EYPTNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
EyePoint, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.44−2.55 (-85.28%)
Close on Oct 19, 2026
- Market cap
- $38.08K
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
93M of 86M shares
Institutional holders
189
25 new, 23 sold out
Net institutional buying
6M
In Q2 2026
Insider trades, 12 months
2 buys · 11 sales
Net sold $1.97M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| JANUS HENDERSON GROUP Ltd. | 9,366,332 | 10.90% | 13G (passive) | Aug 31, 2026 |
| Chen Bihua | 8,265,000 | 9.98% | 13G (passive) amendment | Dec 4, 2025 |
| Cormorant Asset Management, LP | 7,000,000 | 8.35% | 13G (passive) amendment | Jun 30, 2026 |
| Thomas R. Donahue | 6,934,414 | 8.04% | 13G (passive) amendment | Sep 30, 2026 |
| BlackRock, Inc. | 6,430,477 | 7.70% | 13G (passive) amendment | Jun 30, 2026 |
| Adage Capital Management, L.P. | 4,790,792 | 5.71% | 13G (passive) | Jun 30, 2026 |
| Suvretta Capital Management, LLC | 4,774,389 | 9.99% | 13G (passive) amendment | Dec 31, 2023 |
| Phillip Gross | 4,700,000 | 5.68% | 13G (passive) amendment | Dec 31, 2025 |
| Ann C. Donahue | 4,599,450 | 6.68% | 13G (passive) amendment | Jun 30, 2025 |
| Adage Capital Partners, L.P. | 4,466,420 | 9.15% | 13G (passive) amendment | Dec 31, 2023 |
| Michael Kramarz | 4,250,000 | 5.10% | 13G (passive) | May 27, 2026 |
| Vanguard Capital Management | 4,223,415 | 5.03% | 13G (passive) | Jun 30, 2026 |
| Senai Asefaw, M.D. | 4,192,261 | 5.10% | 13G (passive) | Feb 17, 2026 |
| Franklin Resources, Inc. | 4,137,567 | 6.10% | 13G (passive) amendment | Dec 31, 2024 |
| Essex Woodlands Fund IX-GP, L.P. | 2,337,786 | 5.00% | 13D (active) amendment | Dec 4, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of EYPT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 8,296,375 | 9.62% | $118.64M | – | 2.17% |
| BlackRock, Inc. | 7,463,197 | 8.66% | $106.72M | +285,860 | 0.00% |
| Cormorant Asset Management, LP | 7,000,000 | 8.12% | $100.10M | −1,265,000 | 5.13% |
| Federated Hermes, Inc. | 5,681,052 | 6.59% | $81.24M | +11,463 | 0.12% |
| Adage Capital Partners Gp, L.L.C. | 4,827,792 | 5.60% | $69.04M | +1,527,792 | 0.10% |
| Franklin Resources Inc | 4,807,078 | 5.58% | $68.74M | −241,520 | 0.01% |
| Commodore Capital LP | 4,600,000 | 5.34% | $65.78M | +1,775,000 | 3.92% |
| Jupiter Topco LLC | 3,770,381 | 4.37% | $53.90M | New | 0.02% |
| Vanguard Capital Management LLC | 3,630,252 | 4.21% | $51.91M | +70,683 | 0.00% |
| Paradigm Biocapital Advisors LP | 2,890,397 | 3.35% | $41.33M | −252,040 | 0.77% |
| State Street Corp | 2,357,545 | 2.73% | $33.71M | +260,343 | 0.00% |
| Geode Capital Management, LLC | 2,062,390 | 2.39% | $29.50M | +78,725 | 0.00% |
| abrdn plc | 2,008,802 | 2.33% | $28.73M | +270,424 | 0.04% |
| Citadel Advisors LLC | 1,977,610 | 2.29% | $28.28M | +71,735 | 0.00% |
| Balyasny Asset Management L.P. | 1,812,358 | 2.10% | $25.92M | +373,621 | 0.03% |
| Parkman Healthcare Partners LLC | 1,288,163 | 1.49% | $18.42M | −66,637 | 1.89% |
| Eventide Asset Management, LLC | 1,245,583 | 1.44% | $17.81M | – | 0.24% |
| Two Sigma Investments, LP | 1,181,143 | 1.37% | $16.89M | +750,828 | 0.01% |
| Essex Woodlands Management, Inc. | 1,084,857 | 1.26% | $15.51M | – | 6.10% |
| Orbimed Advisors LLC | 1,069,147 | 1.24% | $15.29M | – | 0.28% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 189 | 93M | 100.0% | 25 / 65 | 60 / 23 | 13M | 7M |
| Q1 2026 | 189 | 90M | 100.0% | 47 / 74 | 40 / 22 | 23M | 11M |
| Q4 2025 | 166 | 84M | 97.0% | 33 / 70 | 36 / 16 | 22M | 8M |
| Q3 2025 | 151 | 70M | 81.1% | 27 / 42 | 48 / 18 | 9M | 8M |
| Q2 2025 | 142 | 69M | 80.2% | 22 / 50 | 37 / 30 | 5M | 10M |
| Q1 2025 | 151 | 74M | 86.0% | 25 / 57 | 45 / 18 | 5M | 5M |
| Q4 2024 | 145 | 74M | 86.3% | 29 / 67 | 25 / 21 | 22M | 6M |
| Q3 2024 | 138 | 59M | 68.3% | 21 / 47 | 49 / 34 | 13M | 9M |
| Q2 2024 | 152 | 59M | 68.2% | 26 / 63 | 46 / 36 | 12M | 11M |
| Q1 2024 | 163 | 58M | 67.2% | 56 / 59 | 35 / 31 | 14M | 7M |
| Q4 2023 | 138 | 52M | 59.8% | 56 / 41 | 29 / 15 | 25M | 7M |
| Q3 2023 | 98 | 34M | 39.1% | 24 / 34 | 19 / 8 | 5M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of EYPT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Federated Hermes Kaufmann Fund | 2,771,487 | 3.21% | $33.95M | 0.69% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,643,860 | 3.07% | $37.81M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,021,128 | 2.34% | $28.90M | 0.03% | Jun 30, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 1,982,000 | 2.30% | $24.28M | 0.85% | Jul 31, 2026 |
| Eventide Healthcare & Life Sciences Fund | 1,245,583 | 1.44% | $17.81M | 1.00% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 1,123,495 | 1.30% | $13.76M | 1.19% | Jul 31, 2026 |
| Franklin Small Cap Growth Fund | 1,084,494 | 1.26% | $13.29M | 0.54% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 895,912 | 1.04% | $12.81M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 846,534 | 0.98% | $10.37M | 0.03% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 607,108 | 0.70% | $8.68M | 0.06% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 530,232 | 0.62% | $7.58M | 1.77% | Jun 30, 2026 |
| Columbia Small Cap Growth Fund | 442,348 | 0.51% | $6.01M | 0.16% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 403,146 | 0.47% | $5.47M | 0.01% | May 31, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 399,795 | 0.46% | $4.90M | 0.22% | Jul 31, 2026 |
| Vanguard Russell 2000 Index Fund | 398,338 | 0.46% | $5.41M | 0.03% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jay S. Duker | President and CEO, Director | 187,025 | 0.22% | Jul 14, 2026 |
| George Elston | Chief Financial Officer | 122,470 | 0.14% | Aug 24, 2026 |
| Ramiro Ribeiro | Chief Medical Officer | 4,875 | 0.01% | Jul 2, 2026 |
| Karen L. Zaderej | Director | 49,100 | 0.06% | Aug 18, 2026 |
| Nancy Lurker | Director | 421,235 | 0.49% | Jan 7, 2026 |
| Reginald J. Sanders | Director | – | – | Jan 6, 2026 |
| Wendy F. Dicicco | Director | 9,967 | 0.01% | Jan 6, 2026 |
| John B. Landis | Director | 21,400 | 0.02% | Jan 6, 2026 |
| Stuart Duty | Director | – | – | Jan 6, 2026 |
| Goran Ando | Director | 13,150 | 0.02% | Jan 6, 2026 |
| Fred Hassan | Director | – | – | Jan 6, 2026 |
| Cormorant Asset Management, LP | – | 8,265,000 | 9.59% | Dec 8, 2025 |
| Bihua Chen | – | – | – | Dec 8, 2025 |
| Cormorant Global Healthcare Master Fund, LP | – | 7,288,479 | 8.45% | Dec 8, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| George Elston Chief Financial Officer | Aug 20, 2026 | Gift | +64,953 | – | – | 64,953 |
| George Elston Chief Financial Officer | Aug 20, 2026 | Gift | −64,953 | – | – | 32,517 |
| George Elston Chief Financial Officer | Aug 20, 2026 | Other | +5,000 | – | – | 96,691 |
| George Elston Chief Financial Officer | Aug 20, 2026 | Other | −5,000 | – | – | 25,000 |
| Karen L. Zaderej Director | Aug 18, 2026 | Buy | +10,600 | $4.93 | $52.26K | 49,100 |
| Jay S. Duker President and CEO, Director | Jul 10, 2026 | Tax withholding | −8,059 | $14.72 | $118.63K | 9,594 |
| Jay S. Duker President and CEO, Director | Jul 10, 2026 | Option exercise | +16,667 | – | – | 17,653 |
| Ramiro Ribeiro Chief Medical Officer | Jun 30, 2026 | Option exercise | +2,438 | $8.26 | $20.14K | 4,875 |
| Ramiro Ribeiro Chief Medical Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −2,437 | $15.00 | $36.56K | 2,438 |
| Ramiro Ribeiro Chief Medical Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −2,438 | $15.02 | $36.62K | 0 |
| Ramiro Ribeiro Chief Medical Officer | Jun 30, 2026 | Option exercise | +2,437 | $8.26 | $20.13K | 2,437 |
| George Elston Chief Financial Officer | May 25, 2026 | Tax withholding | −3,627 | $12.93 | $46.90K | 91,691 |
| George Elston Chief Financial Officer | May 25, 2026 | Option exercise | +7,500 | – | – | 95,318 |
| Ramiro Ribeiro Chief Medical Officer | Apr 17, 2026 | Option exercise | +2,437 | $8.26 | $20.13K | 2,437 |
| Ramiro Ribeiro Chief Medical Officer | Apr 17, 2026 | Sale(10b5-1 plan) | −2,437 | $15.00 | $36.56K | 0 |
| Jay S. Duker President and CEO, Director | Mar 23, 2026 | Other | +76,766 | $13.11 | $1.01M | 177,431 |
| Jay S. Duker President and CEO, Director | Mar 23, 2026 | Other | −76,766 | $13.11 | $1.01M | 986 |
| Jay S. Duker President and CEO, Director | Mar 16, 2026 | Buy | +1,500 | $13.15 | $19.73K | 100,665 |
| Ramiro Ribeiro Chief Medical Officer | Mar 4, 2026 | Sale(10b5-1 plan) | −2,438 | $17.87 | $43.57K | 0 |
| Ramiro Ribeiro Chief Medical Officer | Mar 4, 2026 | Option exercise | +2,438 | $8.26 | $20.14K | 2,438 |
| George Elston Chief Financial Officer | Mar 2, 2026 | Gift | −5,000 | – | – | 87,818 |
| George Elston Chief Financial Officer | Mar 2, 2026 | Gift | +5,000 | – | – | 30,000 |
| Ramiro Ribeiro Chief Medical Officer | Feb 17, 2026 | Option exercise | +2,437 | $8.26 | $20.13K | 2,437 |
| Ramiro Ribeiro Chief Medical Officer | Feb 17, 2026 | Sale(10b5-1 plan) | −2,437 | $15.00 | $36.56K | 0 |
| George Elston Chief Financial Officer | Jan 6, 2026 | Option exercise | +15,285 | – | – | 96,339 |
| George Elston Chief Financial Officer | Jan 6, 2026 | Tax withholding | −4,487 | $16.86 | $75.65K | 91,852 |
| Jay S. Duker President and CEO, Director | Jan 6, 2026 | Tax withholding | −10,054 | $16.86 | $169.51K | 77,752 |
| Jay S. Duker President and CEO, Director | Jan 6, 2026 | Option exercise | +20,793 | – | – | 87,806 |
| Nancy Lurker Director | Jan 6, 2026 | Option exercise | +75,133 | – | – | 294,346 |
| Ramiro Ribeiro Chief Medical Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −42,544 | $17.10 | $727.50K | 0 |
| Ramiro Ribeiro Chief Medical Officer | Jan 5, 2026 | Option exercise | +29,250 | $8.26 | $241.61K | 42,544 |
| George Elston Chief Financial Officer | Jan 5, 2026 | Option exercise | +15,000 | – | – | 85,457 |
| George Elston Chief Financial Officer | Jan 5, 2026 | Tax withholding | −4,403 | $17.43 | $76.74K | 81,054 |
| Jay S. Duker President and CEO, Director | Jan 5, 2026 | Tax withholding | −14,505 | $17.43 | $252.82K | 67,013 |
| Jay S. Duker President and CEO, Director | Jan 5, 2026 | Option exercise | +30,000 | – | – | 81,518 |
| Nancy Lurker Director | Jan 5, 2026 | Option exercise | +12,666 | – | – | 219,213 |
| George Elston Chief Financial Officer | Jan 3, 2026 | Option exercise | +19,667 | – | – | 76,781 |
| George Elston Chief Financial Officer | Jan 3, 2026 | Tax withholding | −6,324 | $17.48 | $110.54K | 70,457 |
| Ramiro Ribeiro Chief Medical Officer | Jan 3, 2026 | Option exercise | +19,667 | – | – | 19,667 |
| Ramiro Ribeiro Chief Medical Officer | Jan 3, 2026 | Tax withholding | −6,373 | $17.48 | $111.40K | 13,294 |
| Jay S. Duker President and CEO, Director | Jan 3, 2026 | Tax withholding | −23,447 | $17.48 | $409.85K | 51,518 |
| Jay S. Duker President and CEO, Director | Jan 3, 2026 | Option exercise | +65,000 | – | – | 74,965 |
| George Elston Chief Financial Officer | Dec 19, 2025 | Gift | +5,000 | – | – | 25,000 |
| George Elston Chief Financial Officer | Dec 19, 2025 | Gift | −5,000 | – | – | 57,114 |
| Cormorant Asset Management, LP – | Dec 4, 2025 | Sale | −60,000 | $15.70 | $942.00K | 8,265,000 |
| Nancy Lurker Director | Dec 4, 2025 | Sale(10b5-1 plan) | −9,300 | $15.11 | $140.52K | 206,547 |
| Nancy Lurker Director | Nov 28, 2025 | Sale(10b5-1 plan) | −500 | $14.95 | $7.48K | 215,847 |
| Nancy Lurker Director | Nov 26, 2025 | Sale(10b5-1 plan) | −200 | $14.95 | $2.99K | 216,347 |
| Ramiro Ribeiro Chief Medical Officer | Nov 11, 2025 | Sale(10b5-1 plan) | −2,722 | $11.61 | $31.60K | 0 |
| George Elston Chief Financial Officer | Sep 19, 2025 | Gift | −20,000 | – | – | 62,114 |
| George Elston Chief Financial Officer | Sep 19, 2025 | Gift | +20,000 | – | – | 20,000 |
| Karen L. Zaderej Director | Jul 11, 2025 | Option exercise | +2,000 | – | – | 38,500 |
| Jay S. Duker President and CEO, Director | Jul 10, 2025 | Tax withholding | −7,688 | $11.06 | $85.03K | 9,965 |
| Jay S. Duker President and CEO, Director | Jul 10, 2025 | Option exercise | +16,667 | – | – | 17,653 |
| Nancy Lurker Director | Jul 10, 2025 | Option exercise | +11,111 | – | – | 216,547 |
| Jay S. Duker President and CEO, Director | Jun 23, 2025 | Other | −56,665 | $8.21 | $465.22K | 986 |
| George Elston Chief Financial Officer | May 25, 2025 | Tax withholding | −2,202 | $5.68 | $12.51K | 80,848 |
| George Elston Chief Financial Officer | May 25, 2025 | Option exercise | +7,500 | – | – | 83,050 |
| Karen L. Zaderej Director | May 19, 2025 | Buy | +5,000 | $5.99 | $29.95K | 36,500 |
| Karen L. Zaderej Director | May 16, 2025 | Buy | +5,000 | $5.81 | $29.05K | 31,500 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Nancy Lurker Officer | Jul 22, 2026 | 1,235 | $15.82K | Jul 22, 2026 | Stock Options |
| Nancy Lurker Director | Jul 22, 2026 | 1,235 | $15.82K | Jul 22, 2026 | Stock Options |
| Nancy Lurker Officer | Jul 21, 2026 | 421,235 | $5.50M | Jul 21, 2026 | Stock Options |
| Ribeiro Ramiro Officer | Apr 17, 2026 | 9,750 | $144.40K | Apr 17, 2026 | Exercise of Stock Options |
| Ribeiro Ramiro Officer | Jan 5, 2026 | 53,792 | $940.28K | Jan 5, 2026 | Exercise of Stock Options |
| Nancy Lurker Officer | Dec 4, 2025 | 9,300 | $140.48K | Dec 4, 2025 | Open Market Purchase/RSU's |
| Nancy Lurker Officer | Nov 28, 2025 | 500 | $7.48K | Nov 28, 2025 | Open Market Purchase/RSU's |
| Nancy Lurker Officer | Nov 26, 2025 | 200 | $2.99K | Nov 26, 2025 | Open Market Purchase/RSU's |
| Ribeiro Ramiro Officer | Nov 12, 2025 | 2,722 | $30.89K | Nov 11, 2025 | Employee Stock Purchase Plan |
| P. Adamis Anthony Director | Oct 23, 2024 | 67,100 | $673.35K | Oct 23, 2024 | Stock Option Exercise |
| R. Guyer David Former Director | Oct 15, 2024 | 36,975 | $329.82K | Oct 14, 2024 | RSU Vesting |
| R. Guyer David Director | May 14, 2024 | 71,850 | $897.41K | May 14, 2024 | RSU Vesting |
| S. Jones David Officer | Feb 2, 2024 | 10,104 | $288.07K | Feb 2, 2024 | Exercise of Stock Options |
| S. Jones David Officer | Jan 24, 2024 | 34,442 | $857.95K | Jan 24, 2024 | Exercise of Stock Options |
| Nancy Lurker Director | Jan 24, 2024 | 29,956 | $748.25K | Jan 24, 2024 | Open Market Purchase/RSU's |